31.2 C
New York
Thursday, July 3, 2025

Tag: muscle

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that...

EQT to acquire Europa Biosite, a distributor of life science products

EQT Healthcare Growth to acquire Europa Biosite, a distributor of over ten million high-quality life science reagents to academic and biopharma researchers across Europe...

Nixol Weight Loss Capsules UK & IE Officially Launched- Exploring the Science Behind its Weight Loss Tablets Promises

New York City, NY, July 03, 2025 (GLOBE NEWSWIRE) -- In 2025, Nixol, a plant-based dietary supplement, made its debut in the United Kingdom and Ireland, marking a significant entry into the wellness supplement market. Designed to support healthy weight management, boost metabolism, and curb cravings, Nixol has positioned itself as a natural, vegan-friendly alternative to traditional weight loss solutions. Unlike products that rely on synthetic stimulants or restrictive diets, Nixol leverages a blend of carefully selected, science-backed ingredients to promote sustainable fat reduction and overall well-being. This article provides an in-depth exploration of Nixol’s launch, its formulation, claims, scientific backing, customer feedback, and the broader context of its market entry, while critically examining its potential effectiveness and limitations. Visit Official Website 

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

Effective Testosterone Booster for Men Over 50: TestoPrime Medically Accredited as the Best Testosterone Supplement for Males In 40’s and 50’s

Clinicians’ Choice Testosterone Booster: Medically Reviewed and Endorsed by Leading Experts, Now Available Nationwide Without Prescription
Clinicians’ Choice Testosterone Booster: Medically Reviewed and Endorsed by Leading Experts, Now Available Nationwide Without Prescription

Cinema Muscle Recreations LLC Introduces ‘The Ultimate Eleanor,’ the Definitive Celebration of One of the Most Iconic Movie Cars of All Time, Honoring the...

With a limited initial run of 25 cars, these vehicles are being built by the experts on 'Eleanor,' to commemorate the 25th anniversary of the...

Around one hundred Michelin-starred chefs and traditional cuisine chefs vindicate Catalonia as the region with the best gastronomy in the world

With 62 Michelin-starred restaurants and three establishments ranked among the best in the world, Catalonia aims to reinforce its leadership as a preeminent culinary...

Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of $8.25 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $200.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 2, 2025, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 3,636,363 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

PWR delivers science-driven cellular energy and recovery support as part of Jupiter’s expanding longevity supplement portfolio

Quick Personal Loans in the US for 2025 : Low Credit Finance

Compare Top 2025 Personal Loan Services That Offer Fast Cash Options for Americans With Low Credit
Compare Top 2025 Personal Loan Services That Offer Fast Cash Options for Americans With Low Credit

Altimetrik and SLK Software join forces to create an AI-First Engineering Services Powerhouse

BANGALORE, India, June 28, 2025 /PRNewswire/ -- Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive...

Altimetrik and SLK Software join forces to create an AI-First Engineering Services Powerhouse

BANGALORE, India, June 28, 2025 /PRNewswire/ -- Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive...

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months.

GC Biopharma USA Highlights Innovative Manufacturing Approach to IVIG Safety at 2025 CIS Annual Meeting

Differences in manufacturing processes impact the tolerability of intravenous immune globulin (IVIG) products GC Biopharma's manufacturing process reduces FXIa to undetectable levels – a critical...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMuscle